Aim: The aim was to develop magnetic nanovesicles for chemotherapy and self-controlled hyperthermia that prevent overheating of tissues. Materials & methods: Magnetic nanovesicles containing paclitaxel and a dextran-coated biphasic suspension of La_0.75Sr_0.25MnO₃ and Fe₃O₄ nanoparticles (magnetic nanoparticles) were developed. Results: Encapsulation efficiencies of magnetic nanoparticles and paclitaxel were 67 ± 5 and 83 ± 3%, respectively. Sequential release performed at 37°C for 1 h followed by 44°C for another 1 h (as expected for intratumoral injection), showed a cumulative release of 6.6% (109.6 µg), which was above the IC₅₀ of the drug. In an alternating current magnetic field, the temperature remained controlled at 44°C and a synergistic cytotoxicity of paclitaxel and hyperthermia was observed in MCF-7 cells. Conclusion: Magnetic nanovesicles containing biphasic suspensions La_0.75Sr_0.25MnO₃ and Fe₃O₄ nanoparticles encapsulating paclitaxel have potential for combined self-controlled hyperthermia and chemotherapy. Original submitted 15 May 2012; Revised submitted 7 March 2013